REGULATORY
Japan to Launch CEA “Technical Discussions” under MHLW Research Group
By Kohei Hori May 14, 2026
Japan’s “technical discussions” on the review of its cost-effectiveness assessment (CEA) system will be conducted under an existing health ministry-funded research group, with the first meeting set for this month and discussions expected to be…

LATEST

May 14, 2026
Japan will slash the NHI prices of Eli Lilly’s diabetes therapy Mounjaro (tirzepatide) by 25% and Alnylam Japan’s transthyretin amyloid cardiomyopathy therapy Amvuttra (vutrisiran) by some 15% under the quarterly re-pricing scheme, both effective August…
May 14, 2026
A total of four new medicines will join Japan’s NHI reimbursement price list on May 20, including Recordati Rare Diseases Japan’s myelofibrosis therapy Inrebic (fedratinib), which took 11 months to reach listing after regulatory approval.The…
May 14, 2026
Japan’s Central Social Insurance Medical Council (Chuikyo) on May 13 approved the NHI listing of three regenerative medicine products, including Sumitomo Pharma’s iPSC-derived Parkinson’s disease therapy Amchepry (raguneprocel), all carrying hefty price tags.The three products…

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA